fda glp-1 compounding crackdown october 2025 National Hispanic Medical Association | After compounded drugs were banned, counterfeit versions continued to circulate — and still do today. Understanding the risks and Out of Shortage, Into Controversy:

10.1124/pr.55.1.6 87 MinariT

Recycling endosomes might be returned to the cytoplasmic membrane at a relatively early stage

Compounded formulations allow dose titration and strength customization that standard telemedicine platforms cannot provide, potentially reducing side effects and improving tolerability during initiation

Tirzepatide reaches steady-state concentrations after approximately 4 weeks of weekly dosing due to its 5-day half-life

The pilot program spans 18 months, from July 1, 2026, to December 31, 2027

GLP-1 and GIP-based therapies may be appropriate for individuals with Type 2 diabetes, insulin resistance, or those who are overweight (BMI 2730+) with at least one weight-related condition such as high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease